The number of opioid-related overdose deaths has increased concurrently with rising rates of opioid use nationally.
INTRODUCTION
The number of opioid-related overdose deaths has increased concurrently with rising rates of opioid use nationally. 1 Clinical encounters offer an opportunity to provide high-risk patients with targeted interventions, 2 yet clinicians routinely miss the opportunity to deliver risk reduction counseling and naloxone to appropriate patients 3 due, in part, to knowledge gaps. 4, 5 To better identify physician education targets, we examined how internal medicine trainees' beliefs influence willingness to prescribe naloxone, how residents assess risk of opioidrelated overdose, and concordance between risk assessment and naloxone prescription.
METHODS
The study occurred at an academic medical center in Baltimore, MD, with high rates of opioid use and overdose. IRB deemed our study exempt. We surveyed internal medicine residents and collected information on beliefs and behaviors based on seven clinical vignettes. Each vignette provided patient-specific information including age, medical comorbidities, type, and quantity of opioids, and if opioids were chronically or acutely prescribed. Vignettes incorporated a range of overdose risk factors discussed in the literature: opioid dose > 50-100 morphine milligram equivalents (MME) per day confer a moderate risk, dose > 100 MME/day confer a high risk; presence of co-occurring substance use and history of previous overdose both increase risk of overdose compared to those without similar risk factors. 1 We asked residents the likelihood of overdose risk on a four-point scale (not likely, low, medium, or high) and if they would prescribe naloxone.
We completed bivariate analyses looking at relationship of provider characteristics, history of having prescribed naloxone, and willingness to prescribe in the future using STATA (v.15.0, StataCorp). To analyze clinical vignettes, we collapsed risk assessment as determined by the residents into two categories of overdose likelihood: not likely/low and moderate/high. We defined discordant prescribing as occurring when residents rated patients as not likely or low risk of opioid overdose, but still prescribed naloxone and when residents rated patients as moderate to high risk but, did not prescribe naloxone.
RESULTS
The survey response rate was 68% (N = 97), divided evenly among all training years. Beliefs increasing the willingness to prescribe naloxone included positive attitudes on addiction education and believing naloxone is effective in reducing overdose (Table 1) . Physician demographic factors were not associated with willingness to prescribe naloxone including age (OR 0.83; 95%CI 0.65, 1.07); gender (OR 0.68; 95%CI 0.20, 2.26); race (OR 0.28; 95%CI 0.46, 3.62); or year of training (OR 0.74, 95%CI 0.38, 1.53). Having prescribed naloxone in the past did not increase the residents' likelihood of prescribing naloxone in these vignettes (OR 0.85; 95%CI − 0.16, 4.39).
Residents correctly identified those using illicit opioids at moderate or high risk of overdose; however, they consistently underestimated overdose risk even in those taking high doses of opioids (Table 2) .
Willingness to prescribe naloxone was discordant from the risk assessment. Among those viewed by residents as being at moderate to high risk of overdose, residents prescribed naloxone to only about 50% of patients prescribed opioids compared to 83% misusing opioids and 93% who injected drugs.
DISCUSSION
Physicians-in-training correctly identified patients at the highest risk for opioid-related overdose; however, they underestimated risk for overdose among those receiving prescription opioids. If this holds true for their clinical encounters, Published online November 7, 2018 they may routinely underestimate the risk of overdose and may fail to deliver overdose prevention to patients at risk.
It is disappointing that our residents, despite having positive beliefs about naloxone, did not always prescribe naloxone to patients they identified as having a moderate to high risk for overdose. They may be worried about stigmatizing patients or alienating them by discussing overdose prevention. 6 These concerns may be more pronounced for elderly patients or those with opioid prescriptions. Residents may also assume elderly patients use less opioids overall or use them in less risky ways than younger patients.
Study limitations include being small and from a singleinstitution, limiting its generalizability. Moreover, clinical decisions using vignettes may not generalize to actual clinical decision-making. It does, however, provide some important insight and suggests future directions to explore biases informing overdose risk assessment and naloxone prescribing patterns.
Even when residents identify patients at risk of overdose, they often fail to prescribe naloxone. Systems interventions are needed to remind physicians about all patients for whom a naloxone prescription and appropriate counseling are indicated. Additional research should explore the reasons behind discordant prescribing patterns and help physicians better link risk assessment to naloxone prescription. Underestimated risks in patients prescribed opioids Young man w/ sickle cell disease presenting with acute on chronic pain on baseline of 90 mg MME/day with 15 MME 1-2×/day Medium-high 50 50 44
Elderly female prescribed 100 mg morphine equivalents (MME)/ day chronically Medium-high 60 40 25
Varied risk assessment in patients receiving low-dose opioids chronically or acutely Middle age man w/ femur fracture c/b alcohol withdrawal. Discharged on 7.5 MME every 4 h Medium-high 21 79 52
Elderly woman prescribed 5 MME every 8 h as needed for knee pain Low 63 37 25
Young woman with a history of pancreatitis on 15 MME every 4 h Medium-high 36 64 34 MME morphine milligram equivalents. *Risk factors for risk based on opioid risk (low risk is < 50 MME/day, medium risk is ≥ 50-100 MME/day, > 100 MME/day is high risk); presence of substance use disorder (elevated (medium-high) risk if positive), history of opioid overdose (elevated (high) risk if positive) 
